Neuphoria Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Neuphoria Therapeutics
NEUP Stock   3.72  0.07  1.85%   
Analyzing historical trends in various income statement and balance sheet accounts from Neuphoria Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Neuphoria Therapeutics' valuation are summarized below:
Gross Profit
15.6 M
Profit Margin
(0.61)
Market Capitalization
20 M
Enterprise Value Revenue
0.4136
Revenue
15.6 M
There are currently one hundred twenty fundamental ratios for Neuphoria Therapeutics that can be evaluated and compared over time across peers in the industry. Investors and active traders are advised to check Neuphoria Therapeutics' last-minute fundamental performance against the performance between 2010 and 2025 to make sure the trends are evolving in the right direction. As of 12/28/2025, Market Cap is likely to drop to about 10.9 M. In addition to that, Enterprise Value is likely to grow to about (13.4 B)

Neuphoria Therapeutics Total Revenue

25.15 Million

Check Neuphoria Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neuphoria Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.1 M, Interest Expense of 15.4 K or Other Operating Expenses of 17.8 M, as well as many indicators such as Price To Sales Ratio of 0.41, Dividend Yield of 0.0 or PTB Ratio of 6.0E-4. Neuphoria financial statements analysis is a perfect complement when working with Neuphoria Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Neuphoria Stock
Check out the analysis of Neuphoria Therapeutics Correlation against competitors.
To learn how to invest in Neuphoria Stock, please use our How to Invest in Neuphoria Therapeutics guide.

Neuphoria Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets30 B28.6 B3.7 B
Slightly volatile
Short and Long Term Debt Total122.1 M116.3 M20.1 M
Slightly volatile
Total Current Liabilities4.4 B4.2 B546 M
Slightly volatile
Accounts Payable1.2 B1.2 B149.4 M
Slightly volatile
Cash14.9 B14.2 B1.8 B
Slightly volatile
Cash And Short Term Investments14.9 B14.2 B1.8 B
Slightly volatile
Common Stock Shares Outstanding1.5 M1.6 M49.4 M
Slightly volatile
Liabilities And Stockholders Equity30 B28.6 B3.7 B
Slightly volatile
Non Current Liabilities Total5.6 B5.4 B696.9 M
Slightly volatile
Other Current Assets859 M818.1 M107.7 M
Slightly volatile
Total Liabilities10.1 B9.6 B1.2 B
Slightly volatile
Total Current Assets15.8 B15 B1.9 B
Slightly volatile
Short Term Debt122.1 M116.3 M16.8 M
Slightly volatile
Common Stock20.8 K21.9 K73.9 M
Slightly volatile
Other Current Liabilities3.1 B3 B379.6 M
Slightly volatile
Property Plant And Equipment Net110.7 M105.4 M14.5 M
Slightly volatile
Non Current Assets Total14.2 B13.5 B1.8 B
Slightly volatile
Net Receivables12.5 M11.9 M4.3 M
Pretty Stable
Intangible Assets5 B4.8 B623.1 M
Slightly volatile
Current Deferred Revenue256.3 K181.8 K296.2 K
Pretty Stable
Inventory1.091.15131.4 K
Slightly volatile
Good Will9.1 B8.6 B1.1 B
Slightly volatile
Short Term Investments378.4 K376.4 K334.5 K
Slightly volatile
Capital Lease Obligations344.5 K215.7 K550.2 K
Slightly volatile
Net Invested Capital22.9 M15.8 M31.9 M
Slightly volatile
Long Term Investments95.2 K107.1 K116.8 K
Slightly volatile
Property Plant And Equipment Gross226.3 K238.2 K1.4 M
Slightly volatile
Non Current Liabilities Other505 K531.6 K1.3 M
Pretty Stable
Net Working Capital13.6 M8.4 M19 M
Slightly volatile
Short and Long Term Debt26.5 K29.8 K32.5 K
Slightly volatile

Neuphoria Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.1 M1 M1.4 M
Very volatile
Interest Expense15.4 K16.2 K616.6 K
Pretty Stable
Other Operating Expenses17.8 M25.7 M22.9 M
Pretty Stable
Total Operating Expenses16.7 M24.7 M21.5 M
Pretty Stable
Selling General Administrative8.2 B7.8 B1 B
Slightly volatile
Research Development12.2 M13.8 M14.9 M
Very volatile
Selling And Marketing Expenses146.4 K182.8 K156.4 K
Slightly volatile
Cost Of Revenue963.9 K1 M2.4 M
Pretty Stable
Interest Income152.5 K253.1 K62.7 K
Slightly volatile
Reconciled Depreciation673.5 K596.7 K1.1 M
Slightly volatile

Neuphoria Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow13.3 B12.7 B1.6 B
Slightly volatile
End Period Cash Flow15 B14.3 B1.8 B
Slightly volatile
Stock Based Compensation172 M163.8 M21.3 M
Slightly volatile
Depreciation696 M662.9 M86.2 M
Slightly volatile
Issuance Of Capital Stock13.9 M9.1 M26.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.410.4322 K
Pretty Stable
Days Sales Outstanding156164922
Pretty Stable
Average Payables1 M829.8 K1.5 M
Slightly volatile
Stock Based Compensation To Revenue3.916.152.8857
Slightly volatile
Capex To Depreciation0.00.00.0021
Slightly volatile
Inventory Turnover16.7917.6720.2219
Slightly volatile
Days Of Inventory On Hand23.5521.3825.3024
Pretty Stable
Payables Turnover8.0E-49.0E-41.6622
Slightly volatile
Sales General And Administrative To Revenue0.480.560.6108
Slightly volatile
Average Inventory161.7 K209.4 K268.7 K
Pretty Stable
Research And Ddevelopement To Revenue0.490.5218.2451
Pretty Stable
Capex To Revenue0.00420.00440.0634
Slightly volatile
Cash Per Share9.2 K8.8 K1.1 K
Slightly volatile
Days Payables Outstanding436 K415.3 K53.5 K
Slightly volatile
Intangibles To Total Assets0.260.47020.3887
Slightly volatile
Current Ratio6.493.56354.7325
Slightly volatile
Receivables Turnover2.192.313.8823
Slightly volatile
Average Receivables1.6 M2.2 M4.1 M
Slightly volatile
Revenue Per Share13.9513.283.6746
Slightly volatile
Interest Debt Per Share75.2571.66949.3709
Slightly volatile
Debt To Assets0.00390.00410.1876
Slightly volatile
Graham Number1.261.411.5394
Slightly volatile
Operating Cycle156164928
Pretty Stable
Days Of Payables Outstanding436 K415.3 K53.5 K
Slightly volatile
Ebt Per Ebit1.250.74221.3261
Slightly volatile
Quick Ratio6.473.56354.7163
Slightly volatile
Cash Ratio2.943.36693.5862
Slightly volatile
Days Of Inventory Outstanding23.5521.3825.3024
Pretty Stable
Days Of Sales Outstanding156164922
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.051.151.0029
Very volatile
Fixed Asset Turnover0.190.23.4737
Slightly volatile
Debt Ratio0.00390.00410.1876
Slightly volatile
Price Sales Ratio0.410.4322 K
Pretty Stable
Asset Turnover7.0E-48.0E-40.0806
Slightly volatile

Neuphoria Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap10.9 M11.5 M6.7 B
Pretty Stable

Neuphoria Fundamental Market Drivers

About Neuphoria Therapeutics Financial Statements

Neuphoria Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Neuphoria Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Neuphoria Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Neuphoria Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue181.8 K256.3 K
Total Revenue24 M25.2 M
Cost Of Revenue1 M963.9 K
Stock Based Compensation To Revenue 6.15  3.91 
Sales General And Administrative To Revenue 0.56  0.48 
Research And Ddevelopement To Revenue 0.52  0.49 
Revenue Per Share 13.28  13.95 
Ebit Per Revenue(0.08)(0.09)

Pair Trading with Neuphoria Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Neuphoria Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Neuphoria Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Neuphoria Stock

  0.77RAC Race OncologyPairCorr
  0.85VALN Valneva SE ADRPairCorr

Moving against Neuphoria Stock

  0.7VCEL Vericel Corp OrdPairCorr
  0.64VCYT VeracytePairCorr
  0.57VKTX Viking TherapeuticsPairCorr
  0.53DSGN Design TherapeuticsPairCorr
  0.5DNLI Denali TherapeuticsPairCorr
The ability to find closely correlated positions to Neuphoria Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Neuphoria Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Neuphoria Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Neuphoria Therapeutics to buy it.
The correlation of Neuphoria Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Neuphoria Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Neuphoria Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Neuphoria Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Neuphoria Stock Analysis

When running Neuphoria Therapeutics' price analysis, check to measure Neuphoria Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neuphoria Therapeutics is operating at the current time. Most of Neuphoria Therapeutics' value examination focuses on studying past and present price action to predict the probability of Neuphoria Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neuphoria Therapeutics' price. Additionally, you may evaluate how the addition of Neuphoria Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY